ATE378341T1 - Verfahren zur formulierung antibiotischer verbindungen - Google Patents

Verfahren zur formulierung antibiotischer verbindungen

Info

Publication number
ATE378341T1
ATE378341T1 AT01934937T AT01934937T ATE378341T1 AT E378341 T1 ATE378341 T1 AT E378341T1 AT 01934937 T AT01934937 T AT 01934937T AT 01934937 T AT01934937 T AT 01934937T AT E378341 T1 ATE378341 T1 AT E378341T1
Authority
AT
Austria
Prior art keywords
formulation
carbapenem
antibiotic compounds
lyophilizing
lyophilized
Prior art date
Application number
AT01934937T
Other languages
English (en)
Inventor
Anthony Al-Dehneh
William Hunke
Kathleen Illig
Anand Kanike
Hiren Patel
Scott Reynolds
Stelios Tsinontides
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24806736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE378341(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2000/029869 external-priority patent/WO2001032172A1/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE378341T1 publication Critical patent/ATE378341T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT01934937T 2000-10-27 2001-04-27 Verfahren zur formulierung antibiotischer verbindungen ATE378341T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/698,808 US6548492B1 (en) 1999-10-29 2000-10-27 Process for formulation of carbapenem antibiotic compositions
PCT/US2000/029869 WO2001032172A1 (en) 1999-10-29 2000-10-27 Process for formulation of carbapenem antibiotic compositions

Publications (1)

Publication Number Publication Date
ATE378341T1 true ATE378341T1 (de) 2007-11-15

Family

ID=24806736

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01934937T ATE378341T1 (de) 2000-10-27 2001-04-27 Verfahren zur formulierung antibiotischer verbindungen

Country Status (11)

Country Link
US (1) US6548492B1 (de)
EP (1) EP1332145B1 (de)
JP (1) JP2004512339A (de)
KR (1) KR100756595B1 (de)
CN (1) CN100384845C (de)
AT (1) ATE378341T1 (de)
AU (2) AU6107901A (de)
CA (1) CA2426680C (de)
DE (1) DE60131441T2 (de)
ES (1) ES2295166T3 (de)
WO (1) WO2002034750A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006290416B2 (en) * 2005-09-15 2012-04-12 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of beta-lactam antibiotic
US8632801B2 (en) * 2005-12-28 2014-01-21 Alza Corporation Stable therapeutic formulations
US7455077B2 (en) * 2007-01-10 2008-11-25 Lundman Philip L Inflatable plug with flange
CN101367815B (zh) * 2007-06-28 2012-07-04 山东轩竹医药科技有限公司 六元环甲酰胺取代的巯基吡咯烷碳青霉烯化合物
WO2009075309A1 (ja) * 2007-12-12 2009-06-18 Dainippon Sumitomo Pharma Co., Ltd. 製剤組成物
CN101305964B (zh) * 2008-05-26 2012-01-04 宜兴台玉环境工程设备有限公司 带润湿装置的泡药机
EP2303225B1 (de) 2008-06-11 2013-11-20 Ranbaxy Laboratories Limited Zusammensetzungen des Kohlenstoffdioxid Adduktes von Ertapenem und Polymorphe Formen des Mononatriumsalzes von Ertapenem
WO2012066492A1 (en) * 2010-11-16 2012-05-24 Ranbaxy Laboratories Limited Processes for the preparation of carbapenem antibiotic composition
US8691803B2 (en) * 2011-01-24 2014-04-08 Savior Lifetec Corporation Process for the preparation of antibiotic compounds
CN103181904B (zh) * 2011-12-27 2016-01-20 石药集团中奇制药技术（石家庄）有限公司 一种厄他培南钠冻干制剂及其制备方法
JP6356227B2 (ja) 2013-05-07 2018-07-11 マクマスター ユニバーシティー メタロβラクタマーゼの阻害剤
CN109134469B (zh) * 2013-12-31 2021-10-26 石药集团中奇制药技术（石家庄）有限公司 一种厄他培南钠药物组合物及其制备方法
CN104739828B (zh) * 2013-12-31 2018-11-27 石药集团中奇制药技术（石家庄）有限公司 一种厄他培南钠药物组合物及其制备方法
KR101587420B1 (ko) * 2014-08-20 2016-01-22 주식회사 대웅제약 에르타페넴-함유 동결건조제제의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202298D0 (en) 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
EP0814087A3 (de) * 1996-05-08 1999-04-07 Cypros Pharmaceutical Corporation Teillyophilisierte Fructose-1,6-Diphosphat (FDP) für Einspritzung
UA62920C2 (en) 1996-05-28 2004-01-15 Merck & Co Inc Carbapeneme antibiotic, a composition and a method for the preparation
EP0937079A4 (de) * 1996-10-28 2001-01-24 Merck & Co Inc Stabilisierte antibiotische carbapenem-zusammensetzungen und eine methode zu ihrer herstellung
US6297231B1 (en) 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
US6180783B1 (en) 1997-06-16 2001-01-30 Merck & Co., Inc. Stabilized carbapenem intermediates and improved process for carbapenem synthesis
WO1998057973A1 (en) * 1997-06-16 1998-12-23 Merck & Co., Inc. Stabilized carbapenem intermediates and synthetic use
CA2322658C (en) 1998-03-02 2005-04-12 Merck & Co., Inc. Process for synthesizing carbapenem antibiotics
ATE285770T1 (de) * 1999-10-29 2005-01-15 Merck & Co Inc Verfahren zur herstellung von carbapenem- antibiotika zubereitungen

Also Published As

Publication number Publication date
AU6107901A (en) 2002-05-06
US6548492B1 (en) 2003-04-15
KR100756595B1 (ko) 2007-09-10
EP1332145B1 (de) 2007-11-14
CN1481385A (zh) 2004-03-10
ES2295166T3 (es) 2008-04-16
CA2426680A1 (en) 2002-05-02
KR20030044045A (ko) 2003-06-02
DE60131441D1 (de) 2007-12-27
DE60131441T2 (de) 2008-09-18
AU2001261079B2 (en) 2006-03-16
EP1332145A1 (de) 2003-08-06
WO2002034750A1 (en) 2002-05-02
CA2426680C (en) 2009-08-25
EP1332145A4 (de) 2004-07-28
CN100384845C (zh) 2008-04-30
JP2004512339A (ja) 2004-04-22

Similar Documents

Publication Publication Date Title
ATE378341T1 (de) Verfahren zur formulierung antibiotischer verbindungen
US5536735A (en) Pharmaceutical composition
EP0652751B1 (de) Injizierbares Arzneimittel und Satz, die Omoprazol oder verwandte Verbindungenenthalten
YU29502A (sh) Proces dobijanja 4"-supstituisanog 9-dezokso-9a-aza-9a derivata homoeritromicina a
KR940005636A (ko) 트리아졸릴티오메틸티오 세팔로스포린 염산염, 그의 수화물 결정 및 이들의 제조방법
PT790974E (pt) Acidos 4-biarilbutiricos ou 5-biarilpentanoicos substituidos e seus derivados como inibidores de metaloproteinas de matriz
ATE286501T1 (de) Pyrimidinderivate
RU95105587A (ru) Оптически чистые соединения пиридинилметил сульфинил-1н-бензимидазола, их соли, способы получения, фармкомпозиция, способ лечения
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
RU2007119724A (ru) Композиции, содержащие эктинэсайдин и дисахарид
ATE319702T1 (de) Verfahren zur herstellung von benzothiophen- derivaten
HU9201258D0 (en) Process for the production of medical preparations for treating hiv infections and of their active agents
KR910015562A (ko) 뇌부전 질환치료용 약제, 신규 2-(1-피페라지닐)-4-페닐시클로알카노 피리미딘 유도체, 및 그의 제법
NO159592C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolidinderivater.
JP2003171274A5 (de)
JP2003171274A (ja) 薬剤耐性菌感染症治療のための医薬組成物および消毒剤
ATE285770T1 (de) Verfahren zur herstellung von carbapenem- antibiotika zubereitungen
US20060229262A1 (en) Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant
HU9403502D0 (en) 9 a-n-(n`-carbamoyl) and 9 a-n-(n`-thiocarbamoyl) derivatives 9-deoxo-9a-aza-9a-homoerythro-mycin a
PT1218401E (pt) 4-benzilaminoquinolinas conjugadas com acido biliar e seus heterociclicos metodos de sua producao medicamentos contendo estes compostos e sua aplicacao
US4705803A (en) Method of improving resorption of injected antibacterially active substances or combinations
NO810758L (no) Fremgangsmaate for oekning av den orale absorpsjon av beta-lactamantibiotika
KR101574875B1 (ko) 안정화된 페니실린 복합 현탁 제제
DE60127948D1 (de) Verfahren zur herstellung von avermectinderivaten
CA2428564A1 (en) Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1332145

Country of ref document: EP

EEFA Change of the company name